Article Text

PDF
Intravitreal ziv-aflibercept for the treatment of choroidal neovascularisation associated with conditions other than age-related macular degeneration
  1. Imoro Zeba Braimah1,2,
  2. Michael Stewart3,
  3. Chetan Videkar2,
  4. Chintan J Dedhia2,
  5. Jay Chhablani2
  6. on behalf of ‘Ziv-aflibercept study group’
    1. 1School of Medicine and Dentistry, College of Health Sciences, University of Ghana, Accra, Ghana
    2. 2Srimati Kanuri Santhamma Centre for Vitreo-Retinal diseases, KAR Campus, LV Prasad Eye Institute, Hyderabad, Telangana, India
    3. 3Department of Ophthalmology, Mayo Clinic, Jacksonville, Florida, USA
    1. Correspondence to Dr Jay Chhablani, LV Prasad Eye Institute, Banjara Hills, Road no. 2, Hyderabad, Telangana 500034, India; jay.chhablani{at}gmail.com

    Abstract

    Aim To report the short-term outcomes of eyes with choroidal neovascularisation (CNV) associated with causes other than age-related macular degeneration (AMD) after treatment with intravitreal ziv-aflibercept (IVZ) injections.

    Methods This retrospective study included eyes with non-AMD-related CNV that were treated with IVZ (1.25 mg/0.05 mL) on a pro re nata basis. The primary outcome measure is the mean change in best-corrected visual acuity (BCVA) and secondary outcome measures include the mean change in central macular thickness (CMT) and adverse events.

    Results 23 eyes of 19 patients with CNV due to high myopia (9), macular telangiectasia (4), central serous chorioretinopathy (3), choroidal osteoma (2), choroiditis (2), Best's disease (2) and idiopathic (1) were treated. The mean follow-up period was 4±1.9 months. The median number of IVZ injections was 1 (range, 1–3) and the median treatment-free interval at the time of the final visit was 3 months (range, 1–8). The mean BCVA improved from 0.67 LogMAR to 0.58 LogMAR (p=0.0507). Nine of 23 (39%) eyes had BCVA gains of at least 0.1 LogMAR, 11 (48%) eyes had stable BCVA (within 0.1 LogMAR of baseline) and 3 (13%) eyes had a BCVA decline of at least 0.1 LogMAR at the final visit. The mean CMT improved significantly from baseline until the final visit (22 vs 174.5 μm; p=0.037). No ocular or systemic adverse events were noted.

    Conclusions IVZ improves CMT in patients with CNV associated with causes other than AMD, but improvements in BCVA are modest.

    • Retina

    Statistics from Altmetric.com

    Footnotes

    • Collaborators ‘Ziv-aflibercept study group’ investigators: Rajeev Reddy Pappuru, Taraprasad Das, Padmaja Kumari Rani, Mudit Tyagi, Raja Narayanan, Vivek Dave, Subhadra Jalali, Divya Balakrishnan, Muchai Gachago, Bhushan Uplanchiwar, Kushal Agrawal, Hitesh Agrawal, Remya Paulose, Mahima Jhingan, Vishal Govindhari, Sumit Randhir Singh, Rushil Kumar, Komal Agrawal.

    • Contributors Design (IZB and JC) and conduct (CD, CV and JC) of the study; collection (CV and CD), management (JC, CV and CD), analysis (IZB) and interpretation of the data (IZB, JC and MS) and preparation (IZB, JC and MS), review (IZB, JC and MS) or approval (IZB, MS, CV, JC and CD) of the manuscript.

    • Competing interests None declared.

    • Patient consent Obtained.

    • Ethics approval LV Prasad institutional review board of LVPEI.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Linked Articles

    • At a glance
      Keith Barton James Chodosh Jost B Jonas